Medrio,an e-clinical tech company backed by Questa Capital Management, is gearing up what could be a $600 million-plus sale, sources tell Axios.
Why it matters: Clinical trials are complex and managing data is overwhelming. Medrio's technology helps pharma companies and CROs accelerate study timelines and run them more efficiently.
